Marked reduction of AKT1 expression and deregulation of AKT1-associated pathways in peripheral blood mononuclear cells of schizophrenia patients

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  van Beveren, Nico J M ^a,c   Buitendijk, Gabrielle H S ^a   Swagemakers, Sigrid ^a   Krab, Lianne C ^a   Röder, Christian ^a   de Haan, Lieuwe ^b   van der Spek, Peter ^a   Elgersma, Ype ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c Delta Center for Mental Health Care   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NERVE GROWTH FACTOR; NEUROLEPTIC AGENT; NEUROTROPHIN; PROTEIN KINASE; PROTEIN KINASE 1; UNCLASSIFIED DRUG; PROTEIN KINASE B;

ADULT; APOPTOSIS; ARTICLE; CASE CONTROL STUDY; CELL ADHESION; CELL COUNT; CELL CYCLE REGULATION; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FUNCTIONAL ASSESSMENT; GENE EXPRESSION; GENE REPRESSION; GLUCOSE METABOLISM; HUMAN; IMMUNE SYSTEM; MALE; NERVE CELL; OXIDATIVE STRESS; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; BIOLOGICAL MODEL; BIOTINYLATION; CELL CYCLE; CYTOLOGY; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENOME; METABOLISM; MONONUCLEAR CELL; ONSET AGE;

ADULT; AGE OF ONSET; BIOTINYLATION; CASE-CONTROL STUDIES; CELL ADHESION; CELL CYCLE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENETIC PREDISPOSITION TO DISEASE; GENOME; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MODELS, BIOLOGICAL; PROTO-ONCOGENE PROTEINS C-AKT; SCHIZOPHRENIA;

EID: 84857744201     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032618     Document Type: Article

References (55)

1. Vawter MP, Ferran E, Galke B, Cooper K, Bunney WE, et al. (2004) Microarray screening of lymphocyte gene expression differences in a multiplex schizophrenia pedigree. Schizophr Res 67 (1): 41-52.
2. Middleton FA, Pato CN, Gentile KL, McGann L, Brown AM, et al. (2005) Gene expression analysis of peripheral blood leukocytes from discordant sib-pairs with schizophrenia and bipolar disorder reveals points of convergence between genetic and functional genomic approaches. Am J Med Genet B Neuropsychiatr Genet 136B (1): 12-25.
3. Tsuang MT, Nossova N, Yager T, Tsuang MM, Guo SC, et al. (2005) Assessing the validity of blood-based gene expression profiles for the classification of schizophrenia and bipolar disorder: a preliminary report. Am J Med Genet B Neuropsychiatr Genet 133B (1): 1-5.
4. Glatt SJ, Everall IP, Kremen WS, Corbeil J, Sasik R, et al. (2005) Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia. Proc Natl Acad Sci U S A 102 (43): 15533-15538.
5. Matigian NA, McCurdy RD, Feron F, Perry C, Smith H, et al. (2008) Fibroblast and lymphoblast gene expression profiles in schizophrenia: are non-neural cells informative? PLoS ONE 3 (6): e2412.
6. Sullivan PF, Fan C, Perou CM, (2006) Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet 141B (3): 261-268.
7. Naydenov AV, MacDonald ML, Ongur D, Konradi C, (2007) Differences in lymphocyte electron transport gene expression levels between subjects with bipolar disorder and normal controls in response to glucose deprivation stress. Arch Gen Psychiatry 64 (5): 555-564.
8. Konradi C, (2005) Gene expression microarray studies in polygenic psychiatric disorders: applications and data analysis. Brain Res Brain Res Rev 50 (1): 142-155.
9. Carter CJ, (2006) Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and long-term potentiation, oxidative stress and oligodendrocyte viability. Schizophr Res 86 (1-3): 1-14.
10. Woodgett JR, (2005) Recent advances in the protein kinase B signaling pathway. Curr Opin Cell Biol 17 (2): 150-157.
11. Arguello PA, Gogos JA, (2008) A signaling pathway AKTing up in schizophrenia. J Clin Invest 118 (6): 2018-2021.
12. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA, (2004) Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 36 (2): 131-137.
13. Salem JE, Kring AM, (1998) The role of gender differences in the reduction of etiologic heterogeneity in schizophrenia. Clin Psychol Rev 18 (7): 795-819.
14. Andreasen NC, Flaum M, Arndt S, (1992) The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing dignosis and psychopathology. Arch Gen Psychiatry 49 (8): 615-623.
15. Lai WS, Xu B, Westphal KG, Paterlini M, Olivier B, et al. (2006) Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning. Proc Natl Acad Sci U S A 103 (45): 16906-16911.
16. Schwab SG, Hoefgen B, Hanses C, Hassenbach MB, Albus M, et al. (2005) Further evidence for association of variants in the AKT1 gene with schizophrenia in a sample of European sib-pair families. Biol Psychiatry 58 (6): 446-450.
17. Bajestan SN, Sabouri AH, Nakamura M, Takashima H, Keikhaee MR, et al. (2006) Association of AKT1 haplotype with the risk of schizophrenia in Iranian population. Am J Med Genet B Neuropsychiatr Genet 141B (4): 383-386.
18. Xu MQ, Xing QH, Zheng YL, Li S, Gao JJ, et al. (2007) Association of AKT1 gene polymorphisms with risk of schizophrenia and with response to antipsychotics in the Chinese population. J Clin Psychiatry 68 (9): 1358-1367.
19. Thiselton DL, Vladimirov VI, Kuo PH, McClay J, Wormley B, et al. (2008) AKT1 is associated with schizophrenia across multiple symptom dimensions in the Irish study of high density schizophrenia families. Biol Psychiatry 63 (5): 449-457.
20. Ohtsuki T, Inada T, Arinami T, (2004) Failure to confirm association between AKT1 haplotype and schizophrenia in a Japanese case-control population. Mol Psychiatry 9 (11): 981-983.
21. Turunen JA, Peltonen JO, Pietiläinen OP, Hennah W, Loukola A, et al. (2007) The role of DTNBP1, NRG1, and AKT1 in the genetics of schizophrenia in Finland. Schizophr Res 91 (1-3): 27-36.
22. Norton N, Williams HJ, Dwyer S, Carroll L, Peirce T, et al. (2007) Association analysis of AKT1 and schizophrenia in a UK case control sample. Schizophr Res 93 (1-3): 58-65.
23. Liu YC, Huang CL, Wu PL, Chang YC, Huang CH, et al. (2009) Lack of association between AKT1 variances versus clinical manifestations and social function in patients with schizophrenia. J Psychopharmacol 23 (8): 937-943.
24. Sanders AR, Duan J, Levinson DF, Shi J, He D, et al. (2008) No significant association of 14 candidate genes with schizophrenia in a large European ancestry sample: implications for psychiatric genetics. Am J Psychiatry 165 (4): 497-506.
25. Zhao Z, Ksiezak-Reding H, Riggio S, Haroutunian V, Pasinetti GM, (2006) Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction. Schizophr Res 84 (1): 1-14.
26. Heron-Milhavet L, Khouya N, Fernandez A, Lamb NJ, (2011) Akt1 and Akt2: differentiating the aktion. Histol Histopathol 26 (5): 651-62.
27. Nadri C, Kozlovsky N, Agam G, Bersudsky Y, (2002) GSK-3 parameters in lymphocytes of schizophrenic patients. Psychiatry Res 112 (1): 51-57.
28. Kozlovsky N, Nadri C, Agam G, (2005) Low GSK-3beta in schizophrenia as a consequence of neurodevelopmental insult. Eur Neuropsychopharmacol 15 (1): 1-11.
29. Kandel ES, Hay N, (1999) The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res 253 (1): 210-229.
30. Brazil DP, Yang ZZ, Hemmings BA, (2004) Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 29 (5): 233-242.
31. Brazil DP, Park J, Hemmings BA, (2002) PKB binding proteins. Getting in on the Akt. Cell 111 (3): 293-303.
32. Murray RM, Lewis SW, (1987) Is schizophrenia a neurodevelopmental disorder? Br Med J (Clin Res Ed) 19;295 (6600): 681-682.
33. Weinberger DR, (1987) Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44 (7): 660-669.
34. McGlashan TH, Hoffman RE, (2000) Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch Gen Psychiatry 57 (7): 637-648.
35. Beaulieu JM, Gainetdinov RR, Caron MG, (2007) The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci 28 (4): 166-172.
36. Beaulieu JM, Tirotta E, Sotnikova TD, Masri B, Salahpour A, et al. (2007) Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J Neurosci 27 (4): 881-885.
37. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, et al. (2005) An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122 (2): 261-273.
38. Kapur S, (2003) Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 160 (1): 13-23.
39. Insel TR, (2010) Rethinking schizophrenia. Nature 11;468 (7321): 187-93.
40. van Os J, Kenis G, Rutten BP, (2010) The environment and schizophrenia. Nature 11;468 (7321): 203-12.
41. Iwamoto K, Kato T, (2006) Gene expression profiling in schizophrenia and related mental disorders. Neuroscientist 12 (4): 349-361.
42. Arion D, Unger T, Lewis DA, Levitt P, Mirnics K, (2007) Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. Biol Psychiatry 62 (7): 711-721.
43. Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P, (2000) Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 28 (1): 53-67.
44. Hanson DR, Gottesman II, (2005) Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Med Genet 67.
45. Jones AL, Mowry BJ, Pender MP, Greer JM, (2005) Immune dysregulation and self-reactivity in schizophrenia: do some cases of schizophrenia have an autoimmune basis? Immunol Cell Biol 83 (1): 9-17.
46. Muller N, Schwarz M, (2006) Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox Res 10 (2): 131-148.
47. Rothermundt M, Arolt V, Bayer TA, (2001) Review of immunological and immunopathological findings in schizophrenia. Brain Behav Immun 15 (4): 319-339.
48. Carter CJ, (2009) Schizophrenia Susceptibility Genes Directly Implicated in the Life Cycles of Pathogens: Cytomegalovirus, Influenza, Herpes simplex, Rubella, and Toxoplasma gondii. Schizophr Bull 35 (6): 1163-1182.
49. Buckley PF, Mahadik S, Pillai A, Terry A Jr, et al. (2007) Neurotrophins and schizophrenia. Schizophr Res 94 (1-3): 1-11.
50. van Beveren NJM, van der Spelt JJ, de Haan L, Fekkes D, (2006) Schizophrenia-associated neural growth factors in peripheral blood. A review. Eur Neuropsychopharmacol 16 (7): 469-480.
51. van Nimwegen LJ, Storosum JG, Blumer RM, Allick G, Venema HW, et al. (2008) Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J Clin Endocrinol Metab 93 (2): 572-577.
52. Guest PC, Wang L, Harris LW, Burling K, Levin Y, et al. (2010) Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naïve schizophrenia patients. Mol Psychiatry 15 (2): 118-9.
53. Guest PC, Schwarz E, Krishnamurthy D, Harris LW, Leweke FM, et al. (2011) Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology 36 (7): 1092-6.
54. Freyberg Z, Ferrando SJ, Javitch JA, (2010) Roles of the Akt/GSK-3 and Wnt Signaling Pathways in Schizophrenia and Antipsychotic Drug Action. Am J Psychiatry 167: 388-396.
55. Moskvina V, Craddock N, Holmans P, Nikolov I, Pahwa JS, Green E, Owen MJ, O'Donovan MC, WellcomeTrust Case Control Consortium (2009) Gene-wide analyses of genome-wide association data sets: evidence for multiple common risk alleles for schizophrenia and bipolar disorder and for overlap in genetic risk. Mol Psychiatry 14 (3): 252-60.